These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22526596)

  • 1. Summary.
    Ballow M
    J Clin Immunol; 2012 Sep; 32 Suppl 2():S409. PubMed ID: 22526596
    [No Abstract]   [Full Text] [Related]  

  • 2. The patient, the physician, and the payor: a multiperspective look at the challenges of treating primary immunodeficiency.
    Ballow M
    J Clin Immunol; 2012 Sep; 32 Suppl 2():S421-2. PubMed ID: 22544233
    [No Abstract]   [Full Text] [Related]  

  • 3. Payor issues: barriers to optimal management of patients with primary immunodeficiency.
    Shapiro RS; Boyle M
    J Clin Immunol; 2012 Sep; 32 Suppl 2():S410-4. PubMed ID: 22918575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local and national advocacy support.
    Shapiro RS; Boyle M; Perez EE
    J Clin Immunol; 2012 Sep; 32 Suppl 2(Suppl 2):S423-6. PubMed ID: 22810627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline.
    Shehata N; Palda V; Bowen T; Haddad E; Issekutz TB; Mazer B; Schellenberg R; Warrington R; Easton D; Anderson D; Hume H
    Transfus Med Rev; 2010 Jan; 24 Suppl 1():S28-50. PubMed ID: 19962579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical issues and needs in management of primary immunodeficiency diseases in Latin America.
    Condino-Neto A; Franco JL; Trujillo-Vargas C; Espinosa-Rosales FJ; Leiva LE; Rodriguez-Quiroz F; King A; Lagos M; Oleastro M; Bezrodnik L; Grumach AS; Costa-Carvalho BT; Sorensen RU
    Allergol Immunopathol (Madr); 2011; 39(1):45-51. PubMed ID: 21167629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing and therapy utilization: a discussion of updates on PI treatment guidelines.
    Ballow M
    J Clin Immunol; 2012 Sep; 32 Suppl 2():S415-20. PubMed ID: 22730010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of immunoglobulins and indications for their use.
    Guillevin L
    Curr Opin Allergy Clin Immunol; 2013 Jul; 13 Suppl 2():S53-5. PubMed ID: 23873314
    [No Abstract]   [Full Text] [Related]  

  • 9. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
    Mahadevia PJ
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nursing guidelines for administration of immunoglobulin replacement therapy.
    Younger ME; Aro L; Blouin W; Duff C; Epland KB; Murphy E; Sedlak D;
    J Infus Nurs; 2013; 36(1):58-68. PubMed ID: 23271153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-Related Quality of Life and Patients' Empowerment in the Health Care of Primary Immune Deficiencies.
    Quinti I; Pulvirenti F
    J Clin Immunol; 2017 Oct; 37(7):615-616. PubMed ID: 28819871
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparing routes of IgG administration for primary immunodeficiency disorders.
    Torgerson TR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S85-6. PubMed ID: 22976552
    [No Abstract]   [Full Text] [Related]  

  • 13. The question of when and how. Foreword.
    Alam R
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):xiii-xiv. PubMed ID: 18940568
    [No Abstract]   [Full Text] [Related]  

  • 14. Prioritization of evidence-based indications for intravenous immunoglobulin.
    Orange JS; Ochs HD; Cunningham-Rundles C
    J Clin Immunol; 2013 Aug; 33(6):1033-6. PubMed ID: 23764872
    [No Abstract]   [Full Text] [Related]  

  • 15. Giving intravenous immunoglobulin.
    Scherf R; White-Reid K
    RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of the patient with IgG subclass deficiency and/or selective antibody deficiency.
    Herrod HG
    Ann Allergy; 1993 Jan; 70(1):3-8. PubMed ID: 8424594
    [No Abstract]   [Full Text] [Related]  

  • 17. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].
    Haddad L; Perrinet M; Parent D; Leroy-Cotteau A; Toguyeni E; Condette-Wojtasik G; Hachulla E
    Rev Med Interne; 2006 Dec; 27(12):924-6. PubMed ID: 17011081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions.
    Robinson P; Anderson D; Brouwers M; Feasby TE; Hume H;
    Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S3-8. PubMed ID: 17397767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction.
    Harvey RD
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):71S-72S. PubMed ID: 16229676
    [No Abstract]   [Full Text] [Related]  

  • 20. The assessment and management of primary antibody deficiency.
    Empson M; Sinclair J; O'Donnell J; Ameratunga R; Fitzharris P; Steele R;
    N Z Med J; 2004 Jun; 117(1195):U914. PubMed ID: 15282626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.